Chinese Science Bulletin, Volume 61 , Issue 25 : 2759-2761(2016) https://doi.org/10.1360/N972016-00758

对话王福生: 肿瘤的免疫治疗研究

More info


There is no abstract available for this article.


[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66: 115-132 Google Scholar

[2] Rosenberg S A, Lotze M T, Muul L M, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med, 1985, 313: 1485-1492 Google Scholar

[3] Breakthrough of the year 2013. How we did in 2013 and ······. Science, 2013, 342: 1442 Google Scholar

[4] Porter D L, Levine B L, Kalos M, et al. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med, 2011, 365: 725-733 CrossRef PubMed Google Scholar

[5] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med, 2015, 373: 1627-1639 CrossRef PubMed Google Scholar

[6] Lee J H, Lee J H, Lim Y S, et al. Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 2015, 148: 1383-1391.e6 CrossRef PubMed Google Scholar